Want to see HK:2407 full AI Analyst Report?
Top Page
Gaush Meditech Ltd.
(2407)
Select Model
Select Model
Rating:67Neutral
Price Target:
HK$4.50
▼(-41.10% Downside)
Action:Reiterated
Date:08/08/26
The score is primarily supported by attractive valuation (low P/E and high dividend yield) and a recently more stable financial profile. These positives are tempered by softening fundamentals (revenue decline and margin compression) and weaker technicals versus longer-term moving averages with subdued momentum.
Positive Factors
Improved Balance Sheet
The materially lower debt-to-equity ratio and solid equity base indicate a more stable capital structure than in earlier periods. Reduced leverage should provide greater financial flexibility to support operations, absorb business variability, and fund opportunities without the same balance-sheet strain.
Negative Factors
Revenue Decline
The recent revenue contraction points to a weaker near-term growth trajectory and may reflect softer demand or pricing pressure. If sustained, lower sales would limit operating leverage, reduce resources available for investment, and make it harder for earnings to recover or expand.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet
The materially lower debt-to-equity ratio and solid equity base indicate a more stable capital structure than in earlier periods. Reduced leverage should provide greater financial flexibility to support operations, absorb business variability, and fund opportunities without the same balance-sheet strain.
Read all positive factors
Gaush Meditech Ltd. (2407) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$602.64M
Dividend Yield7.69%
Average Volume (3M)15.86K
Price to Earnings (P/E)6.7
Beta (1Y)0.68
Revenue Growth-5.14%
EPS Growth-22.72%
CountryHK
Employees893
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.52
Shares Outstanding147,887,860
10 Day Avg. Volume22,580
30 Day Avg. Volume15,856
Financial Highlights & Ratios
PEG Ratio2.35
Price to Book (P/B)0.64
Price to Sales (P/S)0.78
P/FCF Ratio9.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.22
Revenue Forecast (FY)HK$1.72B
Gaush Meditech Ltd. Business Overview & Revenue Model
Company Description
Gaush Meditech Ltd., alongside its affiliates, is engaged in the global research, development, manufacturing, and sale of specialized medical devices for ophthalmology, serving markets both within the People's Republic of China and internationally...
Gaush Meditech Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.32B | 1.38B | 1.43B | 1.41B | 1.25B | 1.30B |
| Gross Profit | 606.22M | 633.20M | 663.39M | 691.60M | 625.34M | 609.47M |
| EBITDA | 177.26M | 203.47M | 276.49M | 374.31M | 292.78M | 303.38M |
| Net Income | 75.51M | 96.19M | 92.39M | 173.52M | -349.62M | -190.45M |
Balance Sheet | ||||||
| Total Assets | 2.45B | 2.63B | 2.57B | 2.84B | 2.72B | 2.43B |
| Cash, Cash Equivalents and Short-Term Investments | 358.11M | 440.94M | 518.99M | 833.04M | 814.16M | 609.00M |
| Total Debt | 402.50M | 507.37M | 552.24M | 664.36M | 756.00M | 2.62B |
| Total Liabilities | 788.06M | 921.65M | 978.12M | 1.15B | 1.23B | 3.06B |
| Stockholders Equity | 1.65B | 1.69B | 1.58B | 1.68B | 1.47B | -656.43M |
Cash Flow | ||||||
| Free Cash Flow | 126.15M | 110.47M | 26.57M | 203.44M | 186.41M | 136.44M |
| Operating Cash Flow | 150.10M | 144.23M | 107.78M | 249.04M | 234.42M | 164.49M |
| Investing Cash Flow | -49.19M | 20.82M | 18.55M | -167.65M | -136.04M | 79.83M |
| Financing Cash Flow | -137.73M | -206.60M | -303.09M | -189.94M | 3.08M | 72.84M |
Gaush Meditech Ltd. Technical Analysis
Negative
7.64
Price Trends
4.43
Negative
4.70
Negative
5.32
Negative
Market Momentum
-0.14
Positive
43.60
Neutral
39.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2407, the sentiment is Negative. The current price of 7.64 is above the 20-day moving average (MA) of 4.21, above the 50-day MA of 4.43, and above the 200-day MA of 5.32, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 43.60 is Neutral, neither overbought nor oversold. The STOCH value of 39.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2407.
Gaush Meditech Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.05B | 11.38 | 13.24% | 2.59% | 16.15% | 31.89% | |
67 Neutral | HK$602.64M | 6.66 | 4.52% | 7.69% | -5.14% | -22.72% | |
59 Neutral | HK$2.82B | 27.71 | 4.08% | ― | 94.80% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
48 Neutral | HK$2.55B | -15.14 | -7.65% | ― | 21.23% | 36.89% | |
44 Neutral | HK$432.19M | -0.78 | -28.24% | ― | -38.15% | 25.70% |
* Healthcare Sector Average
HK:2407
Gaush Meditech Ltd.
4.08
-5.43
-57.11%
HK:9996
Peijia Medical Ltd.
3.77
-2.22
-37.06%
HK:1789
AK Medical Holdings Ltd.
4.56
-1.34
-22.75%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-4.67
-78.49%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.70
-0.20
-2.90%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
0.98
-1.77
-64.36%
Gaush Meditech Ltd. Corporate Events
Gaush Meditech Profit Slumps on Softer Revenue as R&D Intensity Remains High
Aug 28, 2026
Gaush Meditech reported interim revenue of RMB595.1 million for the six months ended June 30, 2026, down 8.9% year on year, as net profit fell 57.9% to RMB15.1 million and basic earnings per share declined to RMB0.12. Despite tighter top-line and ...
Gaush Meditech Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Aug 18, 2026
Gaush Meditech Ltd has scheduled a board meeting for August 28, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The board will also consider the declaration of...
Gaush Meditech Grants Heidelberg Exclusive Global Rights to T3 Corneal Imaging System
Aug 17, 2026
Gaush Meditech’s subsidiary Gaush Neotech has signed a five-year exclusive agency agreement with Germany’s Heidelberg Engineering to distribute its T3 corneal confocal microscopy system globally, excluding mainland China. Under the dea...
Gaush Meditech Updates Cayman Registered Office in Corporate Charter
Aug 17, 2026
Gaush Meditech Ltd has updated its seventh amended and restated memorandum and articles of association to reflect the change in its principal share registrar and transfer office in the Cayman Islands. The registered office address now identifies A...
Gaush Meditech Issues Supplemental Profit Warning on Interim Revenue Decline
Aug 3, 2026
Gaush Meditech Ltd., a Cayman Islands-incorporated company listed in Hong Kong under stock code 2407, operates in the medical technology sector and is led by Chairman and Executive Director Gao Tieta with a board comprising executive, non-executiv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.